Anti-HLA-DR10 [Lym-1]

Catalogue Number: AB03430-10.0-ABA

Manufacturer:Vector Laboratories, Inc (ABA)
Type:Recombinant Monoclonal
Alias:CD74; Beta chain HLA-DR; HLA-DR β-chain; β-chain; HLA class II histocompatibility antigen gamma chain; HLA-DR antigens-associated invariant chain; Ia antigen-associated invariant chain; Ii; p33
Shipping Condition:Blue Ice
Unit(s): 200 ug
Host name: Human
Clone: Lym-1
Isotype: IgG1
Immunogen: The original antibody was generated by immunizing mice with tumor cell nuclei preparations as immunogens.
Application: FC, IF, IP, WB, RIA, IHC

Additional Text

Gene ID

972

Gene Name

CD74

Uniprot ID

P04233

Purification

Purified

Antibody Clonality

Recombinant Monoclonal

Storage Note

Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.

Application Notes

This antibody could recognize cell lines of B-cell lineage but not cells of T-cell, myeloid, or erythroid derivation in a live cell radioimmunoassay. Flow cytometric analysis of 22 lymphoma biopsies showed that the majority of B-cell tumors were LYM-1 positive. Approximately 40% of B-cell chronic lymphocytic leukemias were found to be positive with Lym-1. The binding of this antibody to peripheral blot lymphocytes was assessed using indirect immunofluorescence staining. Immunoperoxidase staining of nonlymphoid human organs and tissues revealed weak reactivity of Lym-1. This antibody was also capable of immunoprecipitating HLA-DR10 antigen from Raji cells and ARH-77 myeloma cells. (PMID: 3542194). This antibody also was used for immunohistochemical staining of advanced B-cell NHL tissues from patients (PMID: 10809213). This antibody can be used to identify the HLA-DR variant HLA-DR10 in a western blot (PMID: 8917632). LYM-1 chimeric antigen receptor T cells were demonstrated to exhibit potent anti-tumor effects against B-cell lymphoma (PMID: 29261129).

Short Description

This chimeric human antibody was made using the variable domain sequences of the original Mouse IgG2a format for improved compatibility with existing reagents assays and techniques.